Health ❯ Healthcare ❯ Pharmaceuticals ❯ Drug Development

Alzheimer's Disease

Neumora Halts Navacaprant After Phase 3 KOASTAL Failures

A roughly 35% workforce reduction will fund a pivot to three earlier-stage programs, preserving cash into the third quarter of 2027.

Lilly Launches First Amyloid-Targeting Alzheimer’s Drug in India at Rs 91,688 a Dose

FDA Grants Priority Review to Leqembi Autoinjector for Weekly At-Home Starting Dose

Novartis Licenses SciNeuro’s Brain‑Shuttle Alzheimer’s Antibodies in Deal Worth Up to $1.7 Billion

Novo Nordisk’s Oral Semaglutide Fails to Slow Alzheimer’s in Dual Phase 3 Trials

UK Approves Once-Every-Four-Weeks IV Maintenance Dosing for Leqembi in Early Alzheimer’s

Health Canada Conditionally Authorizes First Alzheimer’s Drug to Slow Early Decline

Australia Registers Alzheimer’s Drug Leqembi With APOE4-Based Restrictions

FDA Clears At-Home Leqembi Injection for Weekly Maintenance in Early Alzheimer’s

Alzheimer Drug Leqembi Launches in Germany and Austria on September 1 Under Strict Conditions

EMA Recommends Restricted Approval for Eli Lilly’s Alzheimer’s Drug Kisunla

NICE Bars New Alzheimer’s Antibodies from NHS Over Cost and Capacity

NICE Poised to Reject NHS Coverage for Breakthrough Alzheimer’s Drugs

Australia Approves Donanemab as First Disease-Modifying Alzheimer’s Therapy

EU Approves First Alzheimer's Drug Targeting Disease Progression

EMA Approves Lecanemab for Early-Stage Alzheimer’s Treatment in EU

NHS Rejects Alzheimer’s Drug Donanemab Despite Promising Results

NHS Declines Coverage for Groundbreaking Alzheimer's Drug Due to High Costs